United States Military HIV Research Program (MHRP) Clinical Trials Unit

Information

  • Research Project
  • 9605090
  • ApplicationId
    9605090
  • Core Project Number
    UM1AI108568
  • Full Project Number
    5UM1AI108568-06
  • Serial Number
    108568
  • FOA Number
    RFA-AI-12-018
  • Sub Project Id
  • Project Start Date
    12/10/2013 - 10 years ago
  • Project End Date
    11/30/2020 - 3 years ago
  • Program Officer Name
    ROBY, GREGG A,
  • Budget Start Date
    12/1/2018 - 5 years ago
  • Budget End Date
    11/30/2019 - 4 years ago
  • Fiscal Year
    2019
  • Support Year
    06
  • Suffix
  • Award Notice Date
    11/13/2018 - 5 years ago
Organizations

United States Military HIV Research Program (MHRP) Clinical Trials Unit

DESCRIPTION (provided by the applicant): The Walter Reed Army Institute of Research (WRAIR) proposes to extend and diversify the existing U.S. Military HIV Research Program (MHRP) Clinical Trials Unit (CTU). The proposed MHRP CTU will leverage its existing network structure-which has been developed with the support of the United States Army, the Division of AIDS (DAIDS) and others-to extend the current DAIDS-funded CTU activity that supports the AIDS Clinical Trials Group at two sites to an additional five sites that will support the DAIDS Vaccine Trial Network. The MHRP CTU will comprise a core management group located at WRAIR in Maryland, United States and seven international Clinical Research Sites (CRS) located in Africa and Asia. These sites will conduct clinical protocols from phase I to phase III efficacy trials and are located in areas with substantial HIV burden and populations suitable to participate in planned vaccine and therapeutic clinical trials. MHRP's experience and innovation in HIV vaccine research and capability to address emerging priorities of HIV cure research will contribute scientifically to the DAIDS vaccine and therapeutics leadership networks. An expanded MHRP CTU will bring DAIDS-and the networks MHRP is proposing affiliation with-highly leveraged clinical research capacity with Department of Defense-supported staff and assets fully supported by Army funding. Specific aims of the proposal include: 1. To provide scientific expertise, development of novel products and innovative vaccine strategies and scientific approaches to contribute to both HIV vaccine development and therapeutic research. 2. To provide highly leveraged clinical trial execution of the DAIDS Vaccine network scientific agenda. 3. To provide highly leveraged clinical trial execution of the DAIDS Therapeutic trial network scientific agenda. RELEVANCE: HIV/AIDS is blunting or reversing indicators of community health. Reducing the toll of AIDS and other infectious diseases has been a goal of U.S. National Security Strategy since 2002. The crucible of efforts to combat the scourge of HIV/AIDS is clinical research leading to an effective HIV vaccine and treatments that cure or limit disease progression. The DAIDS Clinical Trials Network is the vital platform for this effort.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    UM1
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
    1117416
  • Indirect Cost Amount
    0
  • Total Cost
    1117416
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:1117416\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZAI1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    WALTER REED ARMY INSTITUTE OF RESEARCH
  • Organization Department
  • Organization DUNS
    129615428
  • Organization City
    SILVER SPRING
  • Organization State
    MD
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    209107500
  • Organization District
    UNITED STATES